Compare NTST & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTST | PHVS |
|---|---|---|
| Founded | 2019 | 2015 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.8B |
| IPO Year | 2020 | 2020 |
| Metric | NTST | PHVS |
|---|---|---|
| Price | $20.26 | $25.40 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 10 |
| Target Price | $21.15 | ★ $40.70 |
| AVG Volume (30 Days) | ★ 1.6M | 102.7K |
| Earning Date | 05-07-2026 | 01-01-0001 |
| Dividend Yield | ★ 4.36% | N/A |
| EPS Growth | ★ 150.00 | N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $195,006,000.00 | N/A |
| Revenue This Year | $15.47 | N/A |
| Revenue Next Year | $14.57 | N/A |
| P/E Ratio | $252.38 | ★ N/A |
| Revenue Growth | ★ 19.79 | N/A |
| 52 Week Low | $14.00 | $11.51 |
| 52 Week High | $21.30 | $29.80 |
| Indicator | NTST | PHVS |
|---|---|---|
| Relative Strength Index (RSI) | 52.65 | 41.76 |
| Support Level | $17.67 | $24.25 |
| Resistance Level | $21.30 | $26.11 |
| Average True Range (ATR) | 0.40 | 1.12 |
| MACD | -0.14 | -0.19 |
| Stochastic Oscillator | 15.79 | 9.24 |
Netstreit Corp is an internally managed real estate investment trust. The company acquires, owns, and manages single-tenant, retail commercial real estate subject to long-term net leases with high-credit quality tenants across the United States. It focuses on tenants in industries where a physical location is critical to the generation of sales and profits, with a focus on necessity goods and essential services in the retail sector, including home improvement, auto parts, drug stores and pharmacies, general retail, grocers, convenience stores, discount stores, and quick-service restaurants. Majorily operates in U.S. States and Other counties, and derives maximum of revenue from USA.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.